Reset
Showing 2 of 2 academic articles

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosisResearch in context

Matthew Lynch, Sophie Manoy, Peter D. Sly, Claire E. Wainwright et al. • EBioMedicine (2025)

Summary: Background: Ataxia-telangiectasia (A-T) is a rare multisystem disease characterised by neurodegenerative cerebellar ataxia, lung disease, immune deficiency, high cancer risk, and mitochondrial dysfunction. A-T cells demonstrate de...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.ebiom.2025.105840